Transcriptional and epigenetic control of IGF1R gene expression: Implications in metabolism and cancer

Growth Hormone and IGF Research

Volumn 24, Issue 4, 2014, Pages 112-118

  Werner, Haim ^a   Sarfstein, Rive ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; IGF1R; IGF1R promoter; Transcription factors; Tumor suppressors

Indexed keywords

BINDING PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; KRUPPEL LIKE FACTOR 6; RNA BINDING PROTEIN EWS; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; WT1 PROTEIN;

BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL METABOLISM; DISEASE ACTIVITY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE PRODUCT; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; INSULIN LIKE GROWTH 1 RECEPTOR GENE; LOSS OF FUNCTION MUTATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEOMICS; REVIEW; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU GENE; WILM TUMOR PROTEIN 1 GENE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS;

EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 84903710324     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2014.03.006     Document Type: Review

References (70)

1. Cooke D.W., Bankert L.A., Roberts C.T., LeRoith D., Casella S.J. Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem. Biophys. Res. Commun. 1991, 177:1113-1120.
2. Mamula P.W., Goldfine I.D. Cloning and characterization of the human insulin-like growth factor-I receptor gene 5'-flanking region. DNA Cell Biol. 1992, 11:43-50.
3. Werner H., Bach M.A., Stannard B., Roberts C.T., LeRoith D. Structural and functional analysis of the insulin-like growth factor I receptor gene promoter. Mol. Endocrinol. 1992, 6:1545-1558.
4. Werner H., Stannard B., Bach M.A., LeRoith D., Roberts C.T. Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. Biochem. Biophys. Res. Commun. 1990, 169:1021-1027.
5. Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. J. Cell Biol. 1991, 115:887-903.
6. Werner H. Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene 2012, 31:2703-2714.
7. O'Connor R., Kauffmann-Zeh A., Liu Y., Lehar S., Evan G.I., Baserga R., Blattler W.A. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell. Biol. 1997, 17:427-435.
8. Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H.L., Kajstura J., Rubin R., Zoltick P., Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995, 55:2463-2469.
9. Baserga R. The IGF-I receptor in cancer research. Exp. Cell Res. 1999, 253:1-6.
10. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
11. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 2007, 28:20-47.
12. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A., Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 1994, 14:3604-3612.
13. Sell C., Rubini M., Rubin R., Liu J.P., Efstratiadis A., Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11217-11221.
14. Sarfstein R., Belfiore A., Werner H. Identification of IGF-IR gene promoter binding proteins in estrogen receptor positive and ER-depleted breast cancer cells. Cancers 2010, 2:233-261.
15. Beitner-Johnson D., Werner H., Roberts C.T., LeRoith D. Regulation of insulin-like growth factor I receptor gene expression by Sp1: physical and functional interactions of Sp1 at GC boxes and at a CT element. Mol. Endocrinol. 1995, 9:1147-1156.
16. Maor S., Mayer D., Yarden R.I., Lee A.V., Sarfstein R., Werner H., Papa M.Z. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J. Endocrinol. 2006, 191:605-612.
17. Reizner N., Maor S., Sarfstein R., Abramovitch S., Welshons W.V., Curran E.M., Lee A.V., Werner H. The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells. J. Mol. Endocrinol. 2005, 35:135-144.
18. Aiello A., Pandini G., Sarfstein R., Werner H., Manfioletti G., Vigneri R., Belfiore A. HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur. J. Cancer 2010, 46:1919-1926.
19. Narla G., Heath K.E., Reeves H.L., Li D., Giono L.E., Kimmelman A.C., Glucksman M.J., Narla J., Eng F.J., Chan A.M., Ferrari A.C., Martignetti J.A., Friedman S.L. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001, 294:2563-2566.
20. Rubinstein M., Idelman G., Plymate S.R., Narla G., Friedman S.L., Werner H. Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology 2004, 145:3769-3777.
21. Bentov I., Narla G., Schayek H., Akita K., Plymate S.R., LeRoith D., Friedman S.L., Werner H. Insulin-like growth factor-1 regulates Krüppel-like factor-6 gene expression in a p53-dependent manner. Endocrinology 2008, 149:1890-1897.
22. DeGregori J., Johnson D.G. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr. Mol. Med. 2006, 6:739-748.
23. Ma Y., Croxton R., Moorer R.L.J., Cress W.D. Identification of novel E2F1-regulated genes by microarray. Arch. Biochem. Biophys. 2002, 399:212-224.
24. Schayek H., Bentov I., Rotem I., Pasmanik-Chor M., Ginsberg D., Plymate S.R., Werner H. Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Growth Hormon. IGF Res. 2010, 20:68-72.
25. Levine A.J., Feng Z., Mak T.W., You H., Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 2006, 20:267-275.
26. Aylon Y., Oren M. New plays in the p53 theater. Curr. Opin. Genes Dev. 2011, 21:86-92.
27. Werner H., Karnieli E., Rauscher F.J., LeRoith D. Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8318-8323.
28. Idelman G., Glaser T., Roberts C.T., Werner H. WT1-p53 interactions in IGF-I receptor gene regulation. J. Biol. Chem. 2003, 278:3474-3482.
29. Ohlsson C., Kley N., Werner H., LeRoith D. p53 regulates IGF-I receptor expression and IGF-I induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 1998, 139:1101-1107.
30. Prisco M., Hongo A., Rizzo M.G., Sacchi A., Baserga R. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol. Cell. Biol. 1997, 17:1084-1092.
31. Attias-Geva Z., Bentov I., Kidron D., Amichay K., Sarfstein R., Fishman A., Bruchim I., Werner H. p53 regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy. Eur. J. Cancer 2012, 48:1570-1580.
32. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377:1367-1373.
33. Zhang L., Kashanchi F., Zhan Q., Zhan S., Brady J.N., Fornace A.J., Seth P., Helman L.J. Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res. 1996, 56:1367-1373.
34. Lakin N.D., Jackson S.P. Regulation of p53 in response to DNA damage. Oncogene 1999, 18:7644-7655.
35. Heron-Milhavet L., LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J. Biol. Chem. 2002, 277:15600-15606.
36. Girnita L., Girnita A., Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8247-8252.
37. el-Deiry W.S. Regulation of p53 downstream genes. Semin. Cancer Biol 1998, 8:345-357.
38. Nahor I., Abramovitch S., Engeland K., Werner H. The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Hormon. IGF Res. 2005, 15:388-396.
39. Werner H., Bruchim I. IGF-1 and BRCA1 signalling pathways in familial cancer. Lancet Oncol. 2012, 13:e537-e544.
40. Sarfstein R., Maor S., Reizner N., Abramovitch S., Werner H. Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol. Cell. Endocrinol. 2006, 252:241-246.
41. Abramovitch S., Glaser T., Ouchi T., Werner H. BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett. 2003, 541:149-154.
42. Maor S.B., Abramovitch S., Erdos M.R., Brody L.C., Werner H. BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol. Genet. Metab. 2000, 69:130-136.
43. Maor S., Yosepovich A., Papa M.Z., Yarden R.I., Mayer D., Friedman E., Werner H. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett. 2007, 257:236-243.
44. Abramovitch S., Werner H. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene. Horm. Metab. Res. 2003, 35:758-762.
45. Amichay K., Kidron D., Attias-Geva Z., Schayek H., Sarfstein R., Fishman A., Werner H., Bruchim I. BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor I receptor (IGF-IR) gene expression in USC cell lines. Int. J. Gynecol. Cancer 2012, 22:748-754.
46. Schayek H., Haugk K., Sun S., True L.D., Plymate S.R., Werner H. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin. Cancer Res. 2009, 15:1558-1565.
47. Maor S., Papa M.Z., Yarden R.I., Friedman E., Lerenthal Y., Lee S.W., Mayer D., Werner H. Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm. Metab. Res. 2007, 39:179-185.
48. Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A., Rose E.A., Kral A., Yeger H., Lewis W.H., Jones C., Housman D.E. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990, 60:509-520.
49. Gessler M., Poustka A., Cavenee W., Neve R.L., Orkin S.H., Bruns G.A. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990, 343:774-778.
50. Keilholz U., Menssen H.D., Gaiger A., Menke A., Oji Y., Oka Y., Scheibenbogen C., Stauss H., Thiel E., Sugiyama H. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005, 19:1318-1323.
51. Werner H., Shen-Orr Z., Rauscher F.J., Morris J.F., Roberts C.T., LeRoith D. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol. Cell. Biol. 1995, 15:3516-3522.
52. Bentov I., LeRoith D., Werner H. The WT1 Wilms' tumor suppressor gene: a novel target for insulin-like growth factor-I action. Endocrinology 2003, 144:4276-4279.
53. Yuen J.S., Cockman M.E., Sullivan M., Protheroe A., Turner G.D., Roberts I.S., Pugh C.W., Werner H., Macaulay V.M. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 2007, 26:6499-6508.
54. Ladanyi M., Gerald W.L. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 1994, 54:2837-2840.
55. Finkeltov I., Kuhn S., Glaser T., Idelman G., Wright J.J., Roberts C.T., Werner H. Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein. Oncogene 2002, 21:1890-1898.
56. Werner H., Idelman G., Rubinstein M., Pattee P., Nagalla S.R., Roberts C.T. A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Cancer Lett. 2007, 247:84-90.
57. Sarfstein R., Pasmanik-Chor M., Yeheskel A., Edry L., Shomron N., Warman N., Wertheimer E., Maor S., Shochat L., Werner H. Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J. Biol. Chem. 2012, 287:2766-2776.
58. Sehat B., Tofigh A., Lin Y., Trocme E., Liljedahl U., Lagergren J., Larsson O. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci. Signal. 2010, 3:ra10.
59. Aleksic T., Chitnis M.M., Perestenko O.V., Gao S., Thomas P.H., Turner G.D., Protheroe A.S., Howarth M., Macaulay V.M. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res. 2010, 70:6412-6419.
60. Sarfstein R., Werner H. Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology 2013, 154:1672-1679.
61. Wu Y.-C., Zhu M., Robertson D.M. Novel nuclear localization and potential function of insulin-like growth factor-1 receptor/insulin receptor hybrid in corneal epithelial cells. PLoS One 2012, 7(8):e42483.
62. Steenman M.J., Rainier S., Dobry C.J., Grundy P., Horon I.L., Feinberg A.P. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet. 1994, 7:433-439.
63. Vu T.H., Hoffman A. Alterations in the promoter-specific imprinting of the insulin-like growth factor-II gene in Wilms' tumor. J. Biol. Chem. 1996, 271:9014-9023.
64. Wutz A., Smrzka O.W., Schweifer N., Schellander K., Wagner E.F., Barlow D.P. Imprinted expression of the Igf2r gene depends on an intronic CpG island. Nature 1997, 389:745-749.
65. Schayek H., Bentov I., Sun S., Plymate S.R., Werner H. Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp. Cell Res. 2010, 316:1479-1488.
66. Schayek H., Seti H., Greenberg N.M., Sun S., Werner H., Plymate S.R. Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Mol. Cell. Endocrinol. 2010, 323:239-245.
67. Schayek H., Bentov I., Jacob-Hirsch J., Yeung C., Khanna C., Helman L.J., Plymate S.R., Werner H. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer. Horm. Metab. Res. 2012, 44:511-519.
68. Nikoshkov A., Sunkari V., Savu O., Forsberg E., Sergiu-Bogdan C., Brismar K. Epigenetic DNA methylation in the promoters of the Igf1 receptor and insulin receptor genes in db/db mice. Epigenetics 2011, 6:405-409.
69. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
70. Vousden K.H., Ryan K.M. p53 and metabolism. Nat. Rev. Cancer 2009, 9:691-700.